Trial Identifier: | 2693-CL-0307 |
Sponsor: | Astellas Pharma China, Inc. |
Start Date: | July 2020 |
Primary Completion Date: | June 2022 |
Study Completion Date: | June 2022 |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
Language | Description |
Country | Location |
---|---|
China | Beijing, China |
China | Chengdu, China |
China | Fuzhou, China |
China | Guangxi, China |
China | Guangzhou, China |
China | Guizhou, China |
China | Hangzhou, China |
China | Hunan, China |
China | Jiangsu, China |
China | Jinlin, China |
China | Kunming, China |
China | Lanzhou, China |
China | Liuzhou, China |
China | Nanjing, China |
China | Nanning, China |
China | Ningxia Hui Nationality Autonomous Region, China |
China | Shanghai, China |
China | Shanxi, China |
China | Shenzhen, China |
China | Shijiazhuang, China |
China | Suzhou, China |
China | Taiyuan, China |
China | Tianjin, China |
China | Wuhan, China |